首页|期刊导航|中国药物评价|医用镁基材料表面改性技术的研究进展与应用展望

医用镁基材料表面改性技术的研究进展与应用展望OA

Surface Modification of Medical Magnesium-Based Materials:Advances and Perspectives

中文摘要英文摘要

医用镁基材料因其具有生物可降解性、力学相容性与生物活性,在骨科、心血管等医疗器械领域展现出广阔的应用前景.然而,其在生理环境中降解速率过快、局部产气及pH升高等问题限制了临床转化及应用.本研究系统综述了镁的腐蚀机理及其在不同生理环境(如骨组织、血管、消化系统)中面临的挑战,重点总结了近年来针对在骨科、心血管、胆道等部位应用特点的表面改性技术研究进展,包括化学转化、微弧氧化、聚合物涂层、复合涂层等方法在提升镁基材料耐腐蚀性、生物相容性和功能化(如促骨整合、抗菌、促内皮化)方面的应用.研究表明,通过表面改性可有效调控镁基材料的降解行为,实现降解与组织再生的协调匹配,为其在可降解植入医疗器械中的进一步应用提供理论支持与技术路径.

Magnesium-based materials demonstrate significant potential for applications in orthopedic,cardiovascular,and other medi-cal device fields due to their excellent biodegradability,favorable mechanical compatibility,and bioactivity.However,challenges such as excessively rapid degradation rates,localized gas formation,and elevated pH in physiological environments have hindered their clinical translation.This review systematically examines the corrosion mechanisms of magnesium-based materials and the specific challenges it faces in various physiological milieus(e.g.,bone tissue,blood vessels,and the digestive system).It highlights recent advances in sur-face modification technologies,including chemical conversion,micro-arc oxidation,polymer coatings,and composite coatings,to enhance the corrosion resistance,biocompatibility,and functional properties(e.g.,osteogenic promotion,antibacterial effects,and endothelial-ization capability)of these materials.Studies indicate that surface modifications can effectively regulate the degradation behavior of mag-nesium-based materials,achieving synchronized degradation and tissue regeneration.These findings provide both theoretical support and technical strategies for the further development of degradable magnesium-based implantable medical devices.

曲春鸽;江珊;尤茗语;田甜

国家药品监督管理局医疗器械技术审评检查长三角分中心,上海 201210国家药品监督管理局医疗器械技术审评检查长三角分中心,上海 201210国家药品监督管理局医疗器械技术审评检查长三角分中心,上海 201210国家药品监督管理局医疗器械技术审评检查长三角分中心,上海 201210

医药卫生

生物可降解耐腐蚀医疗器械体内外研究

MagnesiumBiodegradableCorrosion resistanceMedical devicesIn vitro and in vivo study

《中国药物评价》 2026 (1)

9-13,5

上海市科学技术委员会项目(24692122800)

评论